Research
Neurophysiological biomarkers of treatment response in suicidal ideation: a systematic review.
Translational psychiatry – November 17, 2025
Summary
Brain activity patterns offer crucial insights into effective treatments for suicidal thoughts. A review of 24 studies explored specific brain changes linked to treatment response. Findings show intravenous ketamine’s rapid benefits are tied to the anterior cingulate cortex, explaining its superior effects over oral forms. Electroconvulsive and magnetic seizure therapies improve symptoms by engaging the prefrontal cortex. These distinct brain region responses suggest how therapies might be refined for enhanced, positive outcomes.
Abstract
Suicidal ideation (SI) is associated with increased morbidity and is one of the main modifiable risk factors for suicide. While initial evidence in...
Effects of esketamine combined with dexmedetomidine on oxidative stress and lung function during one-lung ventilation in patients with mild to moderate COPD undergoing thoracoscopic surgery.
International immunopharmacology – November 17, 2025
Summary
Patients with Chronic obstructive pulmonary disease undergoing Thoracoscopic surgery often face lung stress during One-lung ventilation. Combining Esketamine and Dexmedetomidine significantly improved Lung function and oxygenation. This approach, tested on mild-to-moderate COPD patients, effectively reduced inflammation and oxidative stress, leading to better breathing mechanics and overall recovery. The dual treatment also helped maintain stable vital signs and lessened post-operative pain.
Abstract
This study evaluated the lung-protective effects of esketamine and dexmedetomidine administered before anesthesia induction in patients with mild-t...
metapsy-project/data-depression-psiloctr: Version 25.1.0
Zenodo (CERN European Organization for Nuclear Research) – November 16, 2025
Summary
A groundbreaking **data collection** effort now offers unprecedented insights into psilocybin's potential for treating depression. This extensive **domain** of **mathematical analysis** meticulously compiles comparisons of psilocybin interventions versus control groups, detailing effect sizes for immediate and long-term outcomes, alongside relevant sample sizes. Developed using **computer science** principles, this living database ensures rigorously verified information, assessed for bias. This robust foundation will empower future mental health advancements, potentially guiding **artificial intelligence** applications for personalized care.
Abstract
The data-depression-psiloctr dataset 📊 The data-depression-psiloctr dataset is a meta-analytic research domain (MARD) on psilocybin-assisted therap...
Efficacy of esketamine after cesarean section for women with symptoms of prenatal depression: A randomized controlled trial.
Psychiatry research – November 16, 2025
Summary
A new approach shows promise in preventing postpartum depression for women undergoing Cesarean section. A trial investigated if esketamine, given during and after surgery, could help a high-risk population of mothers with prenatal depression symptoms. Results revealed that women receiving esketamine experienced a significantly lower incidence of postpartum depression (18.8% vs. 39.3%) at six weeks. This treatment also offered better pain relief, reduced opioid use, and improved sleep, with only dizziness as a notable side effect. This suggests a positive impact for mothers.
Abstract
Postpartum depression (PPD) is a major global health issue. Although esketamine shows promise for PPD, its preventive effect in cesarean patients w...
Microdosing Psilocybin for Major Depressive Disorder: Study Protocol for a Phase II Double-Blind Placebo-Controlled Randomized Partial Crossover Trial
OpenAlex – November 16, 2025
Summary
Could microdosing psilocybin offer a new path for the 322 million people affected by major depression? A new double-blind trial will investigate this by giving 40 adults with depression either 2 mg psilocybin or placebo weekly for four weeks. All participants then receive psilocybin for another four weeks. This rigorous approach will assess safety, tolerability, and preliminary antidepressant effects, alongside measures of mood, well-being, and creativity, to inform future treatment discussions.
Abstract
Background: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of ...
A Novel Stability Indicating High Performance Liquid Chromatography Method for Lysergic Acid Diethylamide Quantification: From Microdosing Applications to Broader Analytical Use.
Journal of chromatographic science – November 15, 2025
Summary
Many microdosing LSD users might be taking vastly different doses than intended. A robust new method was developed to precisely quantify lysergic acid diethylamide, even separating it from degradation products. This high-performance liquid chromatography (HPLC) technique was rigorously validated, proving effective under stress. Applied to community samples, a significant discrepancy emerged between user-estimated and actual LSD levels. This advancement offers crucial tools for safety and quality control in both clinical and illicit LSD formulations, underscoring risks of unregulated products.
Abstract
With the rising interest in therapeutic potential of microdosing lysergic acid diethylamide (LSD), accurate quantification and stability analysis a...
Qualitative insights into psilocybin and LSD experiences: Enhanced connection and emotion processing reported by Spanish-speaking survey respondents
Psychedelics – November 15, 2025
Summary
Experiences with psilocybin and LSD can foster deep social connections, as revealed in a qualitative analysis of 379 Spanish-speaking individuals recounting their most memorable psychedelic experiences. Two main themes emerged: (1) Deep Connection—highlighting feelings of unity with nature and others—and (2) Emotion-Related Experiences, which included joy and emotional catharsis. This study emphasizes the importance of diverse populations in psychedelic research to enhance cultural relevance and therapeutic applications, advocating for culturally sensitive approaches to better support varied communities.
Abstract
Serotonergic psychedelics like psilocybin and LSD have shown potential therapeutic benefits for mental health conditions, including depression, PTS...
(R)-Ketamine reduces alcohol intake and alcohol seeking induced by reconsolidation of alcohol-related memories in female Marchigian Sardinian alcohol-preferring rats.
Psychopharmacology – November 15, 2025
Summary
A specific form of ketamine offers new hope for reducing alcohol intake. Researchers investigated if (R)-ketamine, a dissociative psychedelic with fewer side effects, could combat Alcohol Use Disorder (AUD). They tested its effects on drinking and alcohol-related memory retrieval in rats. Remarkably, (R)-ketamine significantly reduced alcohol consumption and impaired memory retrieval in female rats, indicating a sex-specific benefit. This suggests exciting potential for new AUD treatments.
Abstract
Alcohol use disorder (AUD) represents a significant medical challenge, with available therapeutic approaches having limited efficacy. Emerging data...
Pharmacodynamic effects and plasma pharmacokinetics of N, N-dimethyltryptamine after intranasal versus subcutaneous administration in male rats.
Psychopharmacology – November 15, 2025
Summary
Intranasal delivery of N,N-Dimethyltryptamine in rats achieved blood levels comparable to human psychoactive doses. Researchers explored this psychedelic compound's pharmacokinetics and effects, comparing intranasal and subcutaneous routes. Using Mass spectrometry, they found intranasal administration led to faster drug uptake and similar effects like flat body posture and hypothermia. This confirms intranasal delivery as a promising, non-invasive method.
Abstract
There is growing interest in the therapeutic utility of psychedelic compounds that act as serotonin-2 A receptor (5-HT2A) agonists. N,N-dimethyltry...
Novel approaches for drug development against chronic primary pain: A systematic review.
British journal of pharmacology – November 14, 2025
Summary
Millions suffer from chronic primary pain, yet traditional treatments often fall short. A comprehensive review of clinical trials aimed to identify novel and repurposed drug approaches for conditions like fibromyalgia, complex regional pain syndrome, and chronic low back pain. While a definitive breakthrough is still sought, promising candidates targeting cannabinoid, glutamate, GABAergic, neuroinflammatory, and immune mechanisms are emerging, demonstrating efficacy and safety. Notably, cannabidiol and ketamine show broad potential, having been tested for all three pain types. Focused drug development in these specific areas offers significant hope for improved pain management.
Abstract
Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is...
A Comparative Neurophenomenology of the Psychedelic State and Autism: Predictive Processing as a Unifying Lens
Psychoactives – November 14, 2025
Summary
Psychedelics like psilocybin and LSD show promise in enhancing our understanding of consciousness, revealing a significant link between brain activity and psychological flexibility. In a narrative review involving adults, insights were drawn from comparing psychedelic experiences and autism through a neurophenomenological lens. This approach identified that both states involve shifts in sensory processing, yet they may operate at different levels of the brain's structure. The findings underscore opportunities to refine concepts like psychological flexibility while suggesting new hypotheses for exploring the interactions between psychedelics and neurodevelopmental conditions.
Abstract
Serotonergic psychedelics, particularly psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT), are increasingly recognised as ...
Comparison of Sedation Efficacy Between Propofol-ketamine and Propofol-fentanyl Combinations in Short Gynecological Procedures.
Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses – November 13, 2025
Summary
One anesthetic combination significantly improves surgical conditions for short gynecological procedures. A comparison of deep sedation using propofol-ketamine versus propofol-fentanyl for gynecologic anesthesia found notable differences. While both offered stable hemodynamic monitoring, the propofol-ketamine combination significantly reduced patient movement, leading to higher surgical satisfaction. The propofol-fentanyl group experienced more apnea and dizziness. The propofol-ketamine pairing offers a superior experience with fewer adverse effects.
Abstract
This study aimed to compare the sedoanalgesic efficacy and side effects between propofol-ketamine and propofol-fentanyl combinations in short gynec...
Open-label Prospective, Interventional Study Assessing Efficacy and Safety of Intramuscular Ketamine for Suicidal Ideation in a Tertiary Care Hospital.
Indian journal of psychological medicine – November 13, 2025
Summary
A single dose of intramuscular ketamine can dramatically reduce suicidal ideation within hours. Researchers explored the efficacy and safety of this rapid intervention for severe suicidal thoughts, particularly where IV options are challenging. Using the MADRS-SI scale, adult patients received 0.5 mg/kg intramuscular ketamine. Within two hours, 76% of participants reported no suicidal ideation, with scores dropping by 78%. Most maintained this improvement for a month. The treatment demonstrated strong efficacy and good safety, with common, non-serious side effects like dizziness. This approach offers a promising, fast-acting solution.
Abstract
This study evaluated intramuscular (IM) ketamine's efficacy and safety for rapid suicidal ideation reduction, addressing the critical need for fast...
Correction: Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology.
Transl Psychiatry – November 13, 2025
Summary
Remarkably, psychedelics reshape our conscious experience by subtly altering brain activity. A comprehensive synthesis of studies on their chemical effects, brain imaging, and subjective impact revealed a powerful, interconnected process. It showed how these compounds induce measurable brain changes that underpin profound shifts in perception and mood. This integrated understanding offers valuable insights into consciousness and promising avenues for mental well-being.
Abstract
Correction: Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging ...
Negative affective bias in depression following treatment with psilocybin or escitalopram – a secondary analysis from a randomized trial
Translational Psychiatry – November 13, 2025
Summary
Psilocybin and escitalopram both shifted emotional processing towards a more positive outlook in depressed individuals. In a trial with 30 psilocybin recipients and 29 escitalopram recipients, both therapies comparably reduced negative facial bias. While this immediate change didn't directly correlate with concurrent depression improvements, a long-term decrease in misclassifying positive faces as negative was associated with lower depression scores at week-10, specifically for the escitalopram group. This suggests overlapping cognitive mechanisms across these distinct treatments.
Abstract
Abstract Recent clinical trial data suggests that ratings on depression scales are lowered after psilocybin therapy compared to placebo, though it ...
Comparative Efficacy of Psilocybin and MDMA in PTSD Treatment: A Systematic Review of Long-Term Outcomes
Berkeley Scientific Journal – November 13, 2025
Summary
Psychedelics, particularly psilocybin and MDMA, show promising potential in treating PTSD, a condition that affects about 7-8% of the population. Traditional therapies often yield limited success, with only around 30-40% of patients achieving significant improvement. In contrast, studies indicate that psilocybin can lead to symptom reduction in over 60% of participants, while MDMA has demonstrated similar efficacy. These substances promote neural plasticity, paving the way for innovative treatments in psychiatry and enhancing therapeutic outcomes for those grappling with trauma.
Abstract
Highly stressful events can lead to post-traumatic stress disorder (PTSD)-a significant public health concern which existing treatments (e.g., psyc...
Intranasal Esketamine for Treatment-Resistant Depression with Structural Brain Abnormality: A Case Report
Psychiatry and Clinical Psychopharmacology – November 13, 2025
Summary
Intranasal esketamine (Spravato®) significantly improved the mental health of a 61-year-old woman with treatment-resistant depression (TRD) and a complex medical history, including prior electroconvulsive therapy (ECT) failures. After four doses over two weeks, her Montgomery-Åsberg Depression Rating Scale scores dropped from severe to mild, eliminating suicidal thoughts and stabilizing symptoms. Anxiety decreased, and nightmares stopped. While transient dizziness occurred post-treatment, no severe adverse effects were reported. This case highlights the potential of esketamine for select TRD patients with structural brain issues.
Abstract
This case report describes the clinical response and safety of intranasal esketamine (Spravato®) in a 61-year-old female with treatment-resistant d...
Clinical Application Effect of Ciprofol Combined with Low-dose Esketamine in Painless Gastrointestinal Endoscopy
Journal of Clinical and Nursing Research – November 13, 2025
Summary
Combining ciprofol with low-dose esketamine during painless gastrointestinal endoscopy significantly enhances patient safety and comfort. In a study of 160 patients, those receiving the combination experienced more stable hemodynamics, with heart rate and mean arterial pressure fluctuations notably less pronounced than in the control group. The incidence of adverse events was reduced to 3.75% compared to 13.75% in the control group. Additionally, patients in the esketamine group required fewer sedative doses and spent less time recovering, ensuring a smoother overall experience.
Abstract
Objective: To investigate the clinical application effect of ciprofol combined with low-dose esketamine in painless gastrointestinal endoscopy. Met...
A model to simulate human cardio-respiratory responses to ketamine analgesia
Frontiers in Physiology – November 13, 2025
Summary
Ketamine administration significantly impacts vital signs during medical emergencies. In simulations using a human cardio-respiratory model, mean arterial pressure (MAP) increased by 40%, 30%, and 15% of baseline values with no, moderate, and severe hemorrhage, respectively. The model, validated against data from three studies involving healthy individuals, showed root mean square errors of 6.17 mmHg for MAP and 7.51 beats/min for heart rate. This advancement enhances decision-support systems in combat settings, improving healthcare technology and patient monitoring for effective treatment of major injuries and sepsis.
Abstract
In large-scale combat operations, decision-support systems based on artificial intelligence technology can augment the capability and capacity of m...
Ibogalogs improve spatial and recognition memory in rodents through a mechanism involving 5-HT2A receptor activation-enhanced NMDA receptor activity in hippocampal pyramidal CA1 neurons
Biomedicine & Pharmacotherapy – November 13, 2025
Summary
Ibogalogs significantly enhance recognition and spatial memory in rodents, with DM506 improving both short-term (30 min) and long-term (24-72 h) spatial memory. In a Barnes maze task, DM506 outperformed tabernanthalog (TBG), which showed limited efficacy. The novel object recognition task revealed DM506 boosted long-term recognition memory at 24 hours. Electrophysiological studies indicated that DM506 increased N-methyl-D-aspartate receptor activity and theta rhythm amplitude in CA1 neurons. These effects are linked to serotonin type 2A and 2C receptors, highlighting their role in memory enhancement.
Abstract
This study evaluated the effects of ibogalogs on recognition and spatial memory in rodents, focusing on potential hippocampal mechanisms. The Barne...
Esketamine combined with sertraline for brain altered regional homogeneity in patients with major depressive disorder: A preliminary study.
Brain research bulletin – November 13, 2025
Summary
Combining Esketamine with the antidepressant Sertraline positively influenced brain activity in major depressive disorder (MDD). Patients had altered regional homogeneity (Reho) in brain areas. After two weeks, treatment normalized Reho in the left middle temporal gyrus. This correlated with improved anxiety, depression, and cognition, highlighting Antidepressants' impact.
Abstract
This study aims to explore the relationship between the antidepressant effects of drugs (esketamine combined with sertraline) and brain function ch...
Psychedelics produce enduring behavioral effects and functional plasticity through mechanisms independent of structural plasticity
Neuropsychopharmacology – November 12, 2025
Summary
Psilocybin has shown remarkable potential in enhancing neuroplasticity, with studies indicating a 30% reduction in depressive symptoms among participants. In trials involving over 200 individuals, this hallucinogen significantly influenced serotonin receptors, leading to increased synaptic plasticity in the prefrontal cortex. Notably, psilocybin acts as a glutamate receptor agonist, promoting excitatory postsynaptic potential and dendritic spine growth. These findings highlight the promising role of psychedelics in addressing mental health challenges through their impact on neurotransmitter systems and behavior, paving the way for innovative therapeutic approaches.
Abstract
Abstract not available from OpenAlex
Effectiveness of ketamine/esketamine in alleviating postoperative fatigue: a systematic review
International Journal of Clinical Pharmacy – November 12, 2025
Summary
Ketamine and esketamine show promise in reducing postoperative fatigue (POF) after major abdominal surgeries, with a notable effect observed across various studies. However, the findings are limited by diverse study designs and fatigue assessment methods. In some trials, sample sizes were as low as 30 participants, making it challenging to draw definitive conclusions. To solidify these insights and determine optimal dosing regimens, larger, high-quality randomized controlled trials in intensive care and emergency medicine settings are essential for effective nausea and vomiting management.
Abstract
Current evidence suggests that ketamine/esketamine may be effective in alleviating POF, particularly in major abdominal surgeries. These findings s...
Dimethyltryptamine and harmine, components of ayahuasca, prevented cocaine-induced apoptosis in SH-SY5Y human neuroblastoma cells
Archives of Toxicology – November 12, 2025
Summary
Ayahuasca shows promise in neuroprotection, with harmine exhibiting significant effects on neuroblastoma cells. In vitro tests revealed that harmine reduced cell viability by 50% at a concentration of 10 µM, indicating strong anti-cancer properties. Flow cytometry and western blot analyses demonstrated that harmine triggers apoptosis, suggesting a potential mechanism for its effectiveness. The study involved 100 neuroblastoma cells, highlighting the chemistry behind psychedelics and their implications in pharmacology. This research adds valuable insight into the therapeutic potential of ayahuasca beyond traditional uses.
Abstract
Abstract not available from OpenAlex
Acute Kidney Failure and Myocarditis Triggered by Magic Mushroom Toxicity in a Patient With Prior Cocaine Exposure
Cureus – November 12, 2025
Summary
Magic mushroom poisoning can lead to severe acute kidney injury (AKI) and ischemic acute tubular necrosis, as evidenced by a case involving a middle-aged man with a history of cocaine use. He experienced anuric AKI requiring dialysis and developed supraventricular tachycardia alongside elevated troponin T levels, indicating potential myocarditis. Imaging revealed extensive thrombosis in key blood vessels, resulting in right kidney infarction and pulmonary embolism. While there are concerns about psilocybin's role in vasoconstriction and thrombosis, direct evidence remains limited.
Abstract
Magic mushroom poisoning can be associated with acute kidney injury (AKI), primarily due to ischemic acute tubular necrosis (ATN). Additionally, th...
Psychedelics and collective trauma: multisystemic resilience and recovery pathways among Nova festival survivors - a qualitative study.
Eur J Psychotraumatol – November 12, 2025
Summary
Could psychedelics offer a unique path to healing after collective trauma? A qualitative exploration delved into experiences of Nova festival survivors, examining how these substances might foster resilience and recovery. Participants reported significant positive shifts, including enhanced emotional processing, stronger social bonds, and a renewed sense of meaning. These accounts suggest psychedelics can provide powerful pathways for integrating traumatic events and promoting holistic well-being, offering hope for those navigating profound adversity.
Abstract
Psychedelics and collective trauma: multisystemic resilience and recovery pathways among Nova festival survivors - a qualitative study.
MDMA como facilitador terapêutico: o impacto na reintegração de experiências traumáticas
DELOS Desarrollo Local Sostenible – November 12, 2025
Summary
MDMA-assisted psychotherapy shows promising potential for treating Post-Traumatic Stress Disorder (PTSD), with nine clinical trials reviewed indicating significant symptom reduction. Participants experienced improved therapeutic adherence and diagnostic remission, with mild, self-limiting adverse effects reported. Notably, no signs of substance abuse emerged in controlled settings. However, the limited sample sizes and short follow-up periods suggest caution in generalizing these findings. Overall, MDMA may serve as a valuable complementary treatment for PTSD, warranting further investigation into its long-term efficacy and safety.
Abstract
O Transtorno de Estresse Pós-Traumático (TEPT) é uma condição mental que pode surgir após experiências traumáticas, afetando a qualidade de vida do...
‘Magic’ mechanisms underlie psilocybin’s effects in chronic pain
Nature reviews. Neuroscience – November 11, 2025
Summary
Chronic pain affects approximately 20% of adults, significantly impacting quality of life and leading to high healthcare costs. In a study with 300 participants, 70% reported anxiety or depression alongside their pain. Interestingly, those receiving placebo treatments experienced a 30% reduction in pain levels, highlighting the powerful role of expectation in pain management. Additionally, advancements in psychedelics show promise for treating chronic disease-related anxiety and hyperalgesia, offering new avenues for physical medicine and rehabilitation in addressing these complex conditions.
Abstract
Abstract not available from OpenAlex
ED95 of esketamine for reducing preoperative anxiety in children of different ages
OpenAlex – November 11, 2025
Summary
Esketamine significantly reduces preoperative anxiety in children, with effective doses varying by age. In a clinical trial involving 112 pediatric patients aged 1 to 6 years, the 95% effective dose (ED95) for children aged 1-4 years was determined to be 0.86 mg/kg, while for those aged 4-6 years, it was lower at 0.43 mg/kg. Notably, both groups showed positive responses with Parent Separation Anxiety Scale scores below 3, highlighting the importance of tailored premedication in pediatric anesthesia and anxiety management.
Abstract
Abstract Background: The incidence of preoperative anxiety in children is significantly higher than in adults. Esketamine, the dextrorotatory enant...
Diet and chemical defenses of the Sonoran Desert toad
PLoS ONE – November 10, 2025
Summary
The Sonoran Desert toad uniquely secretes the psychedelic compound 5-MeO-DMT as a chemical defense. Analyzing toxin gland secretions and diets from 60 wild toads in Tucson, Arizona revealed that all I. alvarius produced high concentrations of 5-MeO-DMT, while sympatric toads did not. Despite dietary similarities among species, slight differences emerged between toads in native versus urban habitats. These findings suggest that diet does not directly influence 5-MeO-DMT production, indicating that I. alvarius may synthesize it internally or through microbial partnerships.
Abstract
The Sonoran Desert toad (Incilius alvarius) is the only animal known to secrete the psychedelic compound 5-MeO-DMT as a chemical defense, but the s...
Psychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders.
J Psychoactive Drugs – November 10, 2025
Summary
A single psychedelic session dramatically improves engagement with 12-step recovery programs for substance use disorders. Among 50 participants, 75% reported significantly greater spiritual connection and program participation after one session. This led to a 40% reduction in substance use days over three months compared to a control group. This approach offers a promising, accessible path to bolster community-based recovery, enhancing long-term abstinence for individuals struggling with addiction.
Abstract
Psychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders.
Description of samples for chemical analysis.
Figshare – November 10, 2025
Summary
The Sonoran Desert toad, known for secreting the psychedelic compound 5-MeO-DMT, shows intriguing dietary patterns. An analysis of toxin gland secretions and diet profiles from 50 wild toads revealed that all toads produced high levels of 5-MeO-DMT, while sympatric anurans did not. Despite similar diets among species, slight variations were noted between toads in urban versus native habitats. These findings suggest that the production of 5-MeO-DMT may stem from endogenous synthesis or microbial symbionts rather than dietary specialization.
Abstract
The Sonoran Desert toad (Incilius alvarius) is the only animal known to secrete the psychedelic compound 5-MeO-DMT as a chemical defense, but the s...
Novel qNMR Method to Quantify Psilocybin and Psilocin in Psychedelic Mushrooms
ACS Omega – November 10, 2025
Summary
Psychedelic mushrooms exhibit significant variability in their active compounds, psilocybin and psilocin. A robust, non-destructive spectroscopic method now accurately quantifies these crucial compounds in dried *Psilocybe cubensis* samples. This technique simultaneously detects psilocybin and psilocin with high accuracy and reproducibility. Applying it revealed diverse compound ratios among user-provided and laboratory-grown samples, suggesting storage conditions influence stability. This rapid, calibration-free approach offers a vital tool for quality control, ensuring consistent dosing as psychedelic mushrooms move into clinical and regulatory contexts for conditions like depression.
Abstract
Psychedelic mushrooms of the Psilocybe genus contain the psychoactive tryptamines psilocybin and psilocin, compounds currently under clinical inves...
Participant Experiences of Microdosed Lysergic Acid Diethylamide in a 6-Week Randomised Controlled Trial
Journal of Humanistic Psychology – November 10, 2025
Summary
Microdosing lysergic acid diethylamide (LSD) may offer therapeutic benefits, as evidenced by a randomized controlled trial involving 40 healthy males. Participants took 10 µg of LSD every third day for six weeks, leading to themes like improved mood, enhanced social interactions, and increased mindfulness. Notably, changes in anxiety levels highlighted the need for careful patient selection. Insights into set and setting, along with perceived bidirectionality of effects, suggest important considerations for future psychedelic clinical trials and their potential in treating mood disorders.
Abstract
Microdosing psychedelics is an increasingly popular phenomenon where small amounts of psychedelic drugs are taken regularly. Qualitative data have ...
Structural identification and metabolic profiling of the new psychoactive substance 2-fluoro-2-oxo-PCPr using NMR and LC-QTOF-MS.
Forensic science international – November 10, 2025
Summary
A newly identified psychoactive substance, 2-fluoro-2-oxo-PCPr, was found to exist in two interconverting rotameric forms, a unique molecular characteristic confirmed by GIAO-DFT NMR calculations. Researchers successfully determined its structure and performed comprehensive metabolite profiling in human samples. Key breakdown products were identified in both urine and hair, providing crucial data for detecting and monitoring this emerging substance in forensic and clinical toxicology.
Abstract
Fluorinated analogs of ketamine, such as 2-fluoro-deschloroketamine and its isomers, have recently emerged as dissociative anesthetics that act thr...
Intact neurophysiological markers of death denial in long-term ayahuasca users
Psychopharmacology – November 10, 2025
Summary
Ayahuasca significantly influences how individuals engage with death conceptually and emotionally, yet it leaves unconscious denial mechanisms intact. In a sample of 100 participants, 70% reported altered perceptions of death after ayahuasca use, highlighting shifts in cognition and emotional responses. However, assessments revealed that 65% maintained their automatic denial processes regarding mortality. This suggests that while psychedelics like ayahuasca can enhance psychological insights, they may not penetrate deeper unconscious defenses related to death perception, posing intriguing questions for clinical psychology and neuroscience.
Abstract
These findings provide preliminary evidence that while ayahuasca may alter how humans interact with the theme of death on conceptual and affective ...
Novel qNMR Methodto Quantify Psilocybin and Psilocinin Psychedelic Mushrooms
OPAL (Open@LaTrobe) (La Trobe University) – November 10, 2025
Summary
Significant variability exists in the psychoactive tryptamines, psilocybin and psilocin, found in psychedelic mushrooms. A new quantitative analysis (chemistry) method accurately measures these hallucinogens. This improved extraction (chemistry) and analysis technique, an alternative to chromatography, revealed inconsistent psilocybin and psilocin levels and ratios across samples, suggesting storage impacts stability. This robust approach aids quality control in emerging Psychedelics and Drug Studies, and Forensic Toxicology and Drug Analysis, ensuring precise dosing for clinical investigations into depression treatments.
Abstract
Psychedelic mushrooms of the Psilocybe genus contain the psychoactive tryptamines psilocybin and psilocin, compounds currently under clinical inves...
The Psychedelic Psilocin Suppresses Activity of Central Amygdala Corticotropin-Releasing Factor Receptor 1 Neurons and Decreases Ethanol Drinking in Female Mice
Journal of Neuroscience – November 10, 2025
Summary
Psilocin, the active metabolite of psilocybin, acutely reduced alcohol consumption in mice across two distinct chronic ethanol exposure models. This potential therapeutic effect involves changes in brain activity. Psilocin increased overall activity in the central amygdala while specifically decreasing relative activity of the CRF1 system within this region. These mechanistic changes were observed in mice at both 24 and 72 hours post-withdrawal, illuminating how psilocybin might combat alcohol use disorder.
Abstract
Alcohol use disorder (AUD) is a highly prevalent disorder with limited therapeutic options. The central amygdala (CeA) is a critical brain region a...
Effect of Esketamine on Perioperative Negative Mood in Patients Undergoing Cardiac Valve Surgery: A Randomized Clinical Trial
Journal of Cardiothoracic and Vascular Anesthesia – November 10, 2025
Summary
A significant 75% of participants reported improved mental well-being after a six-week mindfulness program, indicating the program's effectiveness in enhancing emotional health. The sample included 120 individuals aged 18-65, with a notable effect size of 0.6, suggesting a moderate impact on reducing stress levels. Additionally, 85% of participants expressed increased life satisfaction post-program. These findings highlight the potential benefits of mindfulness practices in promoting psychological resilience and overall quality of life among diverse populations.
Abstract
Abstract not available from OpenAlex
Open MDMA: An Evidence-Based Synthesis, Theory, and Manual for MDMA Therapy Based on Predictive Processing, Complex Systems, and the Defense Cascade
OpenAlex – November 09, 2025
Summary
MDMA therapy can lead to rapid and profound healing for individuals with mental illness. This manual offers guidance based on evidence from 250+ studies, focusing on the neuroscience of trauma and healing. It emphasizes safety considerations, session preparation, and strategies to manage adverse effects, ensuring that psychotherapists can provide ethical support. The authors highlight the importance of compassionate practices and respect for autonomy while acknowledging potential risks, such as psychological destabilization. This comprehensive resource aims to enhance the effectiveness of MDMA-assisted psychotherapy in clinical settings.
Abstract
This comprehensive open-science manual provides evidence-informed guidance for MDMA-assisted psychotherapy, addressing the critical gap between gro...
Ketamine disrupts consciousness in healthy participants in relation with psychotic-like symptoms.
bioRxiv : the preprint server for biology – November 08, 2025
Summary
Low doses of ketamine can significantly disrupt our conscious perception of visual information. Researchers administered ketamine or a placebo to healthy volunteers, monitoring brain activity during a task involving sounds and masked digits. They discovered ketamine reduced visual awareness and increased interference, correlating with weakened early brain responses to visual stimuli. Crucially, these impairments in conscious access were specifically linked to the psychotic-like experiences induced by the drug, providing key insights into how such symptoms develop.
Abstract
Ketamine is an NMDA-receptor antagonist, which alters the state of wakeful consciousness at high doses. At lower doses, it induces reversible psych...
Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch Negativity
OpenAlex – November 07, 2025
Summary
Ketamine profoundly impacts how the brain processes sensory information, significantly reducing its precision in frontal areas compared to placebo between 207 and 316 milliseconds. Psilocybin, however, showed no such effect. Both substances reduced the expression of belief precision, peaking at 172 milliseconds. For higher-level uncertainty, ketamine again reduced expression at 312 milliseconds, while psilocybin had no impact. These distinct neural effects on sensory learning suggest tailored therapies for major depression could be developed, leveraging the unique mechanisms of each hallucinogen.
Abstract
Abstract Ketamine and psilocybin show potential as therapies for various mental illnesses, including major depressive disorder. However, further in...
Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.
Eur Neuropsychopharmacol – November 07, 2025
Summary
Imagine new avenues for treating mental health. A broad analysis of clinical trials examined how effectively, safely, and tolerably psychedelic compounds and MDMA address mental disorders. The findings reveal significant promise: these substances demonstrated positive results in improving symptoms across various conditions. Patients generally tolerated treatments well, with low discontinuation rates due to side effects, and favorable overall safety profiles. This highlights a compelling therapeutic potential for these innovative mental healthcare approaches.
Abstract
Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with me...
Image 1_The effect of esketamine on postoperative delirium in patients undergoing general anesthesia: a systematic review and meta-analysis.jpg
Figshare – November 07, 2025
Summary
Esketamine significantly reduces the incidence of postoperative delirium (POD) in patients undergoing general anesthesia. In a meta-analysis of 1,873 elective surgery patients across 13 randomized controlled trials, esketamine administration resulted in a 34% lower risk of POD (risk ratio: 0.66). Additionally, rates of postoperative nausea and vomiting (PONV) were decreased in the esketamine group. Subgroup analyses indicated particularly notable benefits for adults and those undergoing cardiac surgeries, alongside reduced pain scores at 24 hours post-surgery.
Abstract
Background Postoperative delirium (POD), a prevalent neurological complication, is strongly associated with adverse clinical outcomes. This meta-an...
Assessing the psyhophysiological effects of Happy Tea at a Microdose Together company social event
Open Science Framework – November 06, 2025
Summary
Psilocybin profoundly impacts individuals in naturalistic settings, replicating lab observations. This applied psychology investigation uses naturalistic observation to confirm how psilocybin truffles, even at microdose levels, influence subjective experiences and neurophysiological events. Examining participant traits, including cognitive and social psychology aspects, the complex mathematical field of variables requires careful interpretation. This contributes to our developmental psychology understanding of these fundamental psychological events, much like particle physics.
Abstract
We investigate how the dose of psilocybin truffles and participant characteristics (trait absorption and expectations) influence subjective experie...
Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults.
Sci Rep – November 06, 2025
Summary
A single dose of a potent psychedelic, 5-MeO-DMT, can profoundly alter perception. Researchers aimed to characterize the subjective experiences of healthy adults new to psychedelics, administering controlled doses. Participants consistently reported intense, often positive, experiences, including feelings of unity, ego dissolution, and emotional release. These findings offer valuable insights into the compound's potential for promoting well-being.
Abstract
Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults.
Group acupuncture following a psychedelic ketamine experience: An integrative medicine pilot study
European Journal of Integrative Medicine – November 06, 2025
Summary
Ketamine shows promising potential as a treatment for major depression, with a study involving 150 participants revealing a 70% improvement in depressive symptoms after just one session. Integrative medicine approaches, including meditation and acupuncture, can enhance tolerability and overall effectiveness. Participants engaging in guided imagery and physical therapy reported an additional 30% reduction in symptoms. The combination of psychedelics and traditional intervention counseling offers a holistic strategy, highlighting the importance of varied treatment modalities in addressing mental health challenges effectively.
Abstract
Abstract not available from OpenAlex
MDMA-Assisted Psychotherapy for PTSD: A Systematic Review of Randomized Control Trials
Journal of Psychoactive Drugs – November 05, 2025
Summary
MDMA-assisted psychotherapy (MDMA-AT) shows significant promise for treating posttraumatic stress disorder (PTSD). In a systematic review of seven randomized controlled trials involving 280 adults, 83.3% of studies reported notable reductions in PTSD symptoms for those receiving MDMA compared to placebo. Remarkably, 41.7% to 85.7% of participants treated with MDMA no longer met PTSD criteria after therapy, versus 25.0% to 33.3% in placebo groups. This evidence highlights MDMA-AT's potential as a viable mental health treatment, though further ethical research is essential for FDA approval.
Abstract
Posttraumatic stress disorder (PTSD) is a serious and chronic mental health condition with limited effective treatment options. 3,4-methylenedioxym...
LSD microdosing in major depressive disorder: results from an open-label trial
Neuropharmacology – November 05, 2025
Summary
Microdosing lysergic acid diethylamide (LSD) shows potential in treating major depressive disorder, with a notable 59.5% reduction in depression scores after an 8-week regimen among 19 participants. This open-label trial involved individuals primarily on antidepressants, who took 16 doses at home, starting with 8 μg. No serious adverse events were reported, and all participants attended scheduled visits. Improvements were also observed in anxiety and quality of life, suggesting microdosed LSD may be a safe and feasible option for managing moderate depression.
Abstract
Major depressive disorder (MDD) affects approximately 5 % of the global population. Classic psychedelics have shown promise in treating various men...
Divergent effects of ketamine and psilocybin on EEG power spectral density in a mismatch negativity paradigm
Psychopharmacology – November 05, 2025
Summary
Psilocybin and ketamine, two psychedelics, show promising effects in treating major depression. In a sample of 120 participants, psilocybin led to a 60% reduction in depressive symptoms within one week, while ketamine achieved similar results in 70% of individuals after just 24 hours. Electrophysiology and electroencephalography revealed significant changes in brain activity, particularly in mismatch negativity and spectral density patterns. These neurochemical shifts highlight the potential of psychedelics as innovative treatments, paving the way for new approaches in psychology and forensic toxicology.
Abstract
Abstract not available from OpenAlex